|
|
Vaccine Detail
|
Tumor antigen-sensitized DC vaccine |
| Vaccine Information |
- Vaccine Name: Tumor antigen-sensitized DC vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor antigen (NCT05023928; NCT05235607)
- Immunization Route: subcutaneous injection
- Description: Tumor antigen-sensitized dendritic cell (DC) vaccines may be an effective therapy against cancer. It can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer. (NCT05023928; NCT05235607)
|
| Host Response |
|
|
| References |
NCT05023928: Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer [https://clinicaltrials.gov/study/NCT05023928]
NCT05235607: Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors [https://clinicaltrials.gov/study/NCT05235607]
|
|
